Clinical Trial Update: Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization

View source ↗

Summary

Clinical trial update evaluating the true PCR-negative rate of frontline dasatinib in early chronic phase chronic myeloid leukemia for therapeutic harmonization…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Seoul St. Mary's Hospital | Conditions: Chronic Myelocytic Leukemia | Status: UNKNOWN